|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 5/24 | (2006.01) | ||
| C07K 16/26 | (2006.01) |
| (11) | Number of the document | 2380592 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11166787.9 |
| Date of filing the European patent application | 2006-11-02 | |
| (97) | Date of publication of the European application | 2011-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2018-03-07 |
| (46) | Date of publication of the claims translation | 2018-05-10 |
| (30) | Number | Date | Country code |
| 736623 P | 2005-11-14 | US |
| (72) |
Zeller, Joerg, US
Poulsen, Kristian, Todd, US
Abdiche, Yasmina, Noubia, US
Pons, Jaume, US
Rosenthal, Arnon, US
Collier, Sierra, Jones, US
|
| (73) |
Teva Pharmaceuticals International GmbH,
Schlüsselstrasse 12, 8645 Jona,
CH
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antagonistinis antikūnas, nukreiptas prieš su kalcitonino genu susijusį peptidą |
| Antagonist antibody directed against calcitonin gene-related peptide |
| Payment date | Validity (years) | Amount | |
| 2024-10-22 | 19 | 347.00 EUR |
| 2025-11-02 |